Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl‐2 protein level in hormone‐refractory prostate cancer cells
Makaleler > Tam Makale · 2008
Yazarlar: B. Karabulut, C. Erten, M.K. Gul, E. Cengiz, B. Karaca, Y. Kucukzeybek, G. Gorumlu, H. Atmaca, S. Uzunoglu, U.A. Sanli, Y. Baran, R. Uslu
Cell Biology International, Uluslararası, Wos, 2008, cilt 33, ss 239-246
DOI: 10.1016/j.cellbi.2008.11.011
Özet
Docetaxel, a semi-synthetic taxane analogue, is used effectively in the treatment of metastatic prostate cancer. Zoledronic acid, the most potent member of bisphosphonates, has shown pleiotropic anti-tumoral effects on prostate cancer cells. We have explored the possible additive/synergistic effects and the apoptotic pathways induced by combination treatment of docetaxel and zoledronic acid in hormone and drug refractory, PC-3 and DU-145 prostate cancer cells. Combination of docetaxel and zoledronic acid synergistically inhibits cell growth in PC-3 and DU-145 cells. Moreover, this effect was due to downregulation of antiapoptotic protein Bcl-2 in PC-3 and DU-145 cells. In conclusion, docetaxel/zoledronic acid combination is potentially a novel and effective approach for the treatment of prostate cancer.